Cell and gene therapies offer the potential to treat a wide range of diseases, many of which have previously been difficult or impossible to treat effectively.

Cell therapy involves the transplantation of cells with the intention to cure or prevent a disease and gene therapy the introduction of genes to replace missing or defective ones. New cell therapies are being developed and tested all the time, often requiring the ex vivo expansion of cells in protocols requiring materials such as growth factors and cytokines produced under Good Manufacturing Practice (GMP). This system of regulations, guidelines, and best practices ensures products, especially drugs, biologics (like cell and gene therapies), and medical devices are consistently produced and controlled to high quality standards.

Qkine have launched a range of our high purity animal free growth factors and cytokines as cell therapy grade with additional quality testing as a high quality value equivalent to other suppliers GMP grade recombinant protein offering. As GMP is not a 'grade' but a collection of guidelines, labeling ‘GMP grade’ can be ambiguous, so we have developed our 'cell therapy grade' range to have clearly defined quality assurance and documentation making it suitable for cell and gene therapy development.

All Qkine cell therapy grade proteins are manufactured in our ISO 9001:2015-certified facility, under ISO 20399:2022 standards with GMP compliance, defined quality criteria and documentation.